1-3 of 3
mirabegron
Close
Sort by
Journal Articles

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Beatrice Drexler, MD, Jakob Passweg, MD, Martin Bigler, Alexandre PA Theocharides, MD, Nathan Cantoni, MD, Peter Keller, MD, Georg Stuessi, MD, Axel Rüfer, MD, Rudolf A. Benz, MD, Geneviève Favre, MD, Alexandar Tzankov, MD, Pontus Lundberg, PhD, Andrea Fuhrer, PhD, Christine Biaggi, Markus G Manz, MD, Mario Bargetzi, MD, Simon Mendez-Ferrer, PhD, Radek C. Skoda, MD
Journal: Blood
Blood (2016) 128 (22): 3108.
https://doi.org/10.1182/blood.V128.22.3108.3108
Published: 2016
Journal Articles

The Measure of Plasma Concentrations Is Crucial in Managing Dabigatran Treatment in Non-Valvular Atrial Fibrillation

Diana Iosub, MD, Rosa Trotti, MD, Franco Piovella, MD
Journal: Blood
Blood (2014) 124 (21): 5088.
https://doi.org/10.1182/blood.V124.21.5088.5088
Published: 2014
Journal Articles

Sympathetic Neuropathy Of The Hematopoietic Stem Cell Niche Is Essential For Myeloproliferative Neoplasms

Lorena Arranz, Ph.D., Abel Sánchez-Aguilera, Ph.D., Joan Isern, Ph.D., Daniel Martín-Pérez, Ph.D., Alexandar Tzankov, M.D., Juerg Schwaller, M.D., Radek C. Skoda, M.D., Simón Méndez-Ferrer, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 268.
https://doi.org/10.1182/blood.V122.21.268.268
Published: 2013